The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
May 1st 2024
Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Air Pollution Alters Gut Microbiome, Increasing Risks for Diabetes, Obesity, Study Says
March 17th 2020Exposure to air pollutants alters the composition of gut microbiota, which increases the risk of obesity, diabetes, gastrointestinal disorders, and other chronic illnesses, according to a study published in Environment International.
Read More
Michael D. Abramoff, MD, PhD, is the Robert C. Watzke, MD Professor of ophthalmology and visual sciences at the University of Iowa Carver College of Medicine. He is also a professor of electrical and computer engineering and a professor of biomedical engineering at the University of Iowa. Abramoff’s research interests include how autonomous artificial intelligence (AI) can be used to improve the lives of patients, with a focus on autonomous AI-based diagnostic and quantification algorithms for retinal disease. He is the founder and executive chairman of IDx Technologies, which developed IDx-DR, an FDA-authorized autonomous AI diagnostic system for the detection of diabetic retinopathy and macular edema. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Abramoff regarding the use of AI in the diagnosis of diabetic retinopathy.
Read More
The FDA granted a fast track designation to Jardiance (empagliflozin) for treatment of chronic kidney disease; a new review in the New England Journal of Medicine urges physicians to prepare for self-managed abortion complications; Alcoholics Anonymous is more effective than other common abstinence treatments.
Read More
New CMS Model Aims to Lower Insulin Costs for Seniors
March 11th 2020Today CMS announced the Part D Senior Savings Model, allowing Medicare Part D prescription drug plans to offer plan choices that provide a range of insulins to beneficiaries, at a maximum $35 copay per 30-day supply throughout the benefit year.
Read More
Cost-effectiveness of Diabetes Treatment Sequences to Inform Step Therapy Policies
March 10th 2020This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Read More
Metabolic Health, Weight Affect Diabetes Risk in Postmenopausal Women
March 4th 2020A study on data from the Women’s Health Initiative found good metabolic health and effective weight management can minimize diabetes risk in postmenopausal women. The study, published in Menopause, the journal of The North American Menopause Society, aimed to determine the relationship between metabolic weight categories with incident diabetes in postmenopausal women aged 50 to 79 years.
Read More
Abbott, DexCom Partner With Insulet to Improve Diabetes Management Technology
February 25th 2020Abbott recently announced a partnership with Insulet Corporation to integrate its glucose-sensing technology with an automated insulin delivery system for patients with diabetes. Specifically, Abbott’s FreeStyle Libre system will become compatible with Insulet’s Omnipod Horizon, in an effort to “offer personalized automated insulin delivery and care for people living with diabetes.”
Read More
FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD
February 24th 2020The FDA approved Eli Lilly’s dulaglutide (Trulicity) for the reduction of major adverse cardiovascular events in adults with type 2 diabetes (T2D), with and without established cardiovascular disease (CVD), according to a press release.
Read More
SGLT2 Inhibitors Benefit All Patients with T2D, Regardless of CVD Diagnosis
February 17th 2020The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors leads to cardiovascular benefits in all patients with type 2 diabetes (T2D), according to a study recently published in the Journal of the American Heart Association.
Read More
Going Paleo? Study Says It's No Better Than Other Diets for Glucose, Insulin Regulation
February 17th 2020There’s not much research available comparing the Paleolithic diet to other popular nutritional plans. A new study sought to scour existing data to see the Paleolithic diet’s effect on glucose and insulin regulation. The data showed no significant impact.
Read More
A Qualitative Look at Feeling "Lost" During Pregnancy With Type 1 Diabetes
February 15th 2020Results showed that managing T1D becomes more intense during pregnancy and in the months that follow childbirth. This is due to the need to be even more vigilant than usual in monitoring blood glucose levels and dosing insulin, tasks the women performed mostly themselves, but which can also be performed by other healthcare professionals.
Read More
First Nations Women of Canada Have Higher Diabetes Rates, Study Finds
February 11th 2020Data collected between 1995 and 2014 show prevalence and incidence of diabetes are substantially higher in First Nations people in Canada compared to other people in Ontario, according to a study published in the Canadian Medical Association Journal.
Read More
In 1 Illinois District, Residents' Main Concern: Healthcare, Drug Costs, Legislator Says
February 11th 2020Atul Grover, MD, PhD, the executive vice president for the Association of American Medical Colleges, sat down with Representative Lauren Underwood, D-Illinois, for a conversation about her healthcare-related efforts during her first year in Congress representing people from a suburban rural district 2 hours from Chicago.
Read More
Scientists Capture High-Resolution Imaging of Glucagon-Like Peptide-1 Receptors
January 27th 2020For the first time, scientists obtained high-definition images of glucagon-like peptide-1 receptors, enabling future research into treatments for type 2 diabetes, according to a study published in Nature Communications.
Read More
Jeffrey D. Dunn, PharmD, MBA, has served as vice president of clinical strategy and programs and industry relations at MagellanRx, a national pharmacy benefit manager (PBM); cofounder, senior vice president, chief clinical officer, and board member of VRx, a regional PBM; and pharmacy director of SelectHealth, part of Intermountain Healthcare. Dunn was instrumental in opening and running the VRx retail pharmacy in downtown Salt Lake City, Utah. He is a board member of Care Pharmacies Cooperative, a chain of 100 retail pharmacies. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Dunn regarding the recent Institute for Clinical and Economic Review report on the cost-effectiveness of oral semaglutide.
Read More
PBMI Analysis Finds Jardiance Use Could Save Employers Thousands of Dollars
January 24th 2020Results from an analysis conducted by the Pharmacy Benefit Management Institute (PBMI) show that the use of Jardiance (empagliflozin) among employees with type 2 diabetes and cardiovascular disease can save employers around $737,000 per 10,000 covered lives each year.
Read More
School Snack Regulation Could Reduce Childhood Type 2 Diabetes Rates
January 16th 2020The implementation of the Smart Snacks in School standards in 310 public schools resulted in healthier dietary intakes among students compared with those without the standards, according to a JAMA study published January 15.
Read More